Mar 5, 2019
MedCity's Company of the Month: MediSieve
MediSieve selected at MedCity's Company of the Month. MedCity support and grow the world-leading life sciences ecosystem of the Greater South East of England.
LONDON – March 05, 2019 – Last month MediSieve received £1.56 million in funding from Innovate UK to further develop the use of their magnetic blood filtration technology with a focus on treating sepsis. Founder and CEO, Dr George Frodsham talks to MedCity about pivotal moments in MediSieve’s journey and how it has benefitted from being positioned in the life sciences ecosystem of London and the Greater South East.
The company is delighted to be chosen as MedCity's Company of the Month.
You can read the feature HERE.
Launched in April 2014 to promote and grow the world-leading life sciences cluster of England’s Greater South East, MedCity promotes life sciences investment, entrepreneurship and industry in the region.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: